Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) announced that a joint company secretary, Ms. Jin Jin, resigned effective 6 February 2026 for personal development reasons. Ms. Jin confirmed no disagreements with the board, and the board expressed gratitude for her contributions.

Effective on the same date, Ms. Yang Dongyan was appointed as a joint company secretary. Ms. Yang, aged 40, holds a bachelor’s degree in law from the East China University of Political Science and Law and served previously as a lawyer, partner in a law firm, and legal director of the group. She will share the company secretary duties with the existing joint company secretary, Ms. Sze Suet Ling, who has over 15 years of experience in corporate governance and is a Chartered Secretary and Chartered Governance Professional.

In conjunction with this personnel change, Guangzhou Innogen Pharmaceutical Group Co., Ltd. obtained a waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules for three years from 6 February 2026. During the waiver period, Ms. Sze will continue assisting Ms. Yang. The waiver may be revoked if the listing rules are materially breached. Before the waiver period ends, the company must demonstrate that Ms. Yang has gained sufficient experience to discharge the functions of company secretary without further waiver.

The board welcomed Ms. Yang on her appointment effective 6 February 2026.